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Abstract
Interleukin-27 (IL27) is a type-I cytokine of the IL6/IL12 family and is predominantly secreted
by activated macrophages and dendritic cells. We show that IL27 induces STAT factor phospho-
rylation in cancerous cell lines of different tissue origin. IL27 leads to STAT1 phosphorylation
and recapitulates an IFN-𝛾-like response in the microarray analyses, with up-regulation of genes
involved in antiviral defense, antigen presentation, and immune suppression. Like IFN-𝛾 , IL27
leads to an up-regulation of TAP2 and MHC-I proteins, which mediate increased tumor immune
clearance. However, both cytokines also upregulate proteins such as PD-L1 (CD274) and IDO-1,
which are associatedwith immune escape of cancer. Interestingly, differential expression of these
geneswas observedwithin the different cell lines andwhen comparing IL27 to IFN-𝛾 . In coculture
experiments of hepatocellular carcinoma (HCC) cells with peripheral blood mononuclear cells,
pre-treatment of the HCC cells with IL27 resulted in lowered IL2 production by anti-CD3/-CD28
activated T-lymphocytes. Addition of anti-PD-L1 antibody, however, restored IL2 secretion.
The levels of other TH1 cytokines were also enhanced or restored upon administration of
anti-PD-L1. In addition, we show that the suppression of IL27 signaling by IL6-type cytokine pre-
stimulation—mimicking a situation occurring, for example, in IL6-secreting tumors or in tumor
inflammation–induced cachexia—can be antagonized by antibodies against IL6-type cytokines
or their receptors. Therapeutically, the antitumor effects of IL27 (mediated, e.g., by increased
antigen presentation)might thus be increased by combining IL27with blocking antibodies against
PD-L1 or/and IL6-type cytokines.
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1 INTRODUCTION
The heterodimeric interleukin 27 (IL27), composed of the noncova-
lently linked subunits p28 and EBI3 (Epstein-Barr virus induced gene
3), is related to the IL12-type-cytokines IL12, IL23, and IL35 composed
of two heterodimeric subunits, which are either covalently linked
(IL12, IL23) or not (IL27, IL35). IL27 signals via a receptor complex
composed of the IL27-specific receptor chain IL27R𝛼 (WSX1)1 and the
common receptor subunit of IL6-type cytokines, IL6R𝛽 (gp130).2 Thus,
IL27 is also related to the IL6-type cytokines, as the IL6- and IL12-type
cytokines form a common superfamily.
Cytokines such as interferons, IL2, IL12, IL7, IL15, IL27, and oth-
ers are tested as potential anticancer immuno-stimulatory agents
and some have progressed into clinical trials.3–5 IFN-𝛾 is one of
those cytokines long known to be involved in antitumor defense,
because IFN-𝛾R and STAT1 deficiency has been described to increase
cancer susceptibility upon treatment with chemical pathogens in
mice.6,7 Interferon adjuvant therapy has unfortunately invariably been
reported to have high toxicity, for example, in hepatocellular carci-
noma (HCC) patients.8 Also the antitumor effects of other cytokines
such as IL12 have been attributed to expression of IFN-𝛾 .9,10 IL27 has
been described to have pro- or anti-inflammatory functions in differ-
ent systems11–14 and it is capable of exerting antitumor effects. IL27
seems to be better tolerated than interferons8 and IL1215 in preclini-
cal models, probably because less IFN-𝛾 is released by IL27 compared
to IL12. Combination of IL27 and IL2 has been shown to be strongly
synergistic in a murine neuroblastoma model.16 Treg levels were sup-
pressed and IFN-𝛾 levels elevated for the combination treatment com-
pared to the single treatments. IL2 therapy in humans has been shown
to have a relatively low risk of severe side effects, although it was only
effective in 10–20% of the patients.17–19 Therefore it still remains to
be seenwhether a combination of IL27 and IL2will bemore effective—
as in themurinemodel—and still well tolerated.
IL27 is discussed to be a candidate cytokine for therapeutic
approaches and acts on both the cancer cells themselves and on
immune cells. IL27 has been shown to enhance antitumor immune
responses20–25 via, for example, CD8+ T cells23 or NK cells.26,27 IL27
is involved in TH1 commitment by suppressing GATA3 (GATA binding
protein 3), inducing T-bet, resulting in IL-12R𝛽2 expression in naïve T
cells, thereby supporting the IL12-dependent IFN-𝛾 secretion.1,28–30
It activates CD8+ cells, NK cells, induces TH1 responses and acts on
endothelial cells to secrete anti-angiogenic factors, as does IFN-𝛾 .13
IL27 also induced antibody-dependent cell-mediated cytotoxicity
(ADCC).31 IL27 has also been described to limit IL2 production
by T-cells during TH1 differentiation.
32 The promotion of CD8+ T-,
NK or TH1-cells leads to the production of IFN-𝛾 and other TH1
cytokines that promote differentiation of M1 macrophages. The M1
macrophages secrete cytokines such as IFN-𝛾 , IL12, TNF-𝛼, and IL1,
whichpromote cancer clearancebyTH1-,NK-cells, andCTLs (reviewed
in33–36). IL12 also induces differentiation of mature dendritic cells
(DCs) that present cancer antigens on their surface. Recently, IL27
has emerged as an important immune-regulatory cytokine, antag-
onizing the development of TH17 cell responses,
34–38 which have
cancer promoting effects (e.g., angiogenesis promoting functions).39
Immunosuppressive inducible Foxp3+ and Foxp3− regulatory T cells
(iTreg) are also inhibited by IL27.40–45 Thus the effects of IL27 on
the immune system show a profile that might be compatible with
its proposed function as an anticancer cytokine (see also Supporting
Information Fig. 5).
IL27 does, however, not only act on immune cells but can also
elicit antitumor responses in cancer cells directly, such as antiprolif-
erative, pro-apoptotic, anti-angiogenic, and anti-metastatic functions,
which have recently been reviewed extensively.13 Briefly, IL27 showed
antiproliferative effects on variousmelanoma cell lines46 and, like IFN-
𝛾 , inhibition of angiogenesis.20,47 The growth of poorly immunogenic
B16/F10 melanoma tumors in syngeneic mice was reduced when the
cells had been transfectedwith scIL27.15 We have previously reported
IFN-𝛾-like responses and antiviral activity of IL27 in hepatoma cells,
primary hepatocytes, and hepatic stellate cells,48,49 as has also been
described for other cell types.13,24,50
We have described before that IL27 signaling is susceptible to inhi-
bition by SOCS3, which is induced, for example, upon phosphorylation
of STAT3 by IL6-type cytokines.50 Many tumors have been shown to
secrete IL6-type cytokines and/or to have constitutive STAT3 activa-
tion (and thus elevated SOCS3 levels).51–53 In addition, IL6 has been
shown to be crucial for colorectal cancer and HCC development.54–56
In cancer cachexia, IL6 and other pro-inflammatory cytokines are
produced due to a tumor-induced systemic inflammation.57,58
IL6 and TNF-𝛼 blockade have been used successfully to suppress
cancer cachexia.59,60
Here we describe that IL27 can stimulate cancer cells of differ-
ent lineages and further characterize IL27 signaling in these cell
lines. Microarray analysis showed that IL27 induced an IFN-𝛾-like,
STAT1-dependent transcriptional response, mediating, for example,
up-regulation of genes associatedwith increased tumor immune clear-
ance and also mediating gene expression profiles associated with can-
cer immune escape, for example, PD-L1 and IDO-1 up-regulation.
We show that IL27-induced PD-L1 can suppress IL2 production by
peripheral blood mononuclear cells (PBMCs) and that this effect can
be rescued by anti-PD-L1 antibody administration. Additionally, we
used an IL6-type cytokine pre-stimulation approach to mimic tumor
inflammation–mediated STAT3- and SOCS3-dependent IL27 inhibi-
tion and we show that this inhibition can be prevented by blocking
anti-IL6, -IL6R, or -OSM antibodies.
2 MATERIALS AND METHODS
2.1 Materials and cell culture
Different cancer and noncancer cell lines were used: HCC cell lines
(HepG2, Hep3B, Huh7), a normal hepatocyte cell line (PH5CH8),
melanoma cell lines (A375, MeWo, IGR39, IGR37, FM55P, FM55M1),
normal human epidermal melanocytes (NHEM), colon carcinoma
cell lines (HCT116 and HT29), normal colon mucosa epithelial cells
(NCM460), epidermoid carcinoma cells (A431), epithelial cervix carci-
noma (HELA), breast adenocarcinoma cells (MCF7), and fibrosarcoma
cells (2C4).
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All cells were grown in a water-saturated atmosphere at 5% CO2
and at 37◦C. HepG2, Hep3B, Huh7, PH5CH8, A431, MCF7, HELA,
and 2C4 cells weremaintained in DMEMmedium (Lonza, Switzerland)
supplemented with 10% fetal bovine serum (FBS) (Gibco, USA), 100
ug/L streptomycin and 60 mg/L penicillin (Lonza) and 25 mM HEPES
(Lonza). A375, MeWo, IGR39, IGR37, FM55P, FM55M1 were main-
tained in RPMI (Lonza), whereas HCT116 and HT29 were maintained
in DMEM/F12 (Lonza), bothmedia being supplementedwith 10% FBS,
100 mg/L streptomycin, 60 mg/L penicillin. NHEM were maintained
in melanocyte growth medium M2 (PromoCell, Germany). NCM460
were maintained in M3:BaseA (Incell, USA) supplemented with 10%
fetal bovine serum.
Cells were stimulated according to the molecular masses of the
different cytokines, with 20 ng/mL human recombinant OSM, IL6,
and IFN-𝛾 (Peprotech, USA), 50 ng/mL IL27 (R&D Systems, USA),
or 40 ng/mL hyper-IL6 (hy-IL6) (provided by Prof. Dr. Stefan Rose-
John, University of Kiel, Germany) unless stated otherwise in the
figure legends.
The blocking antibodies used to antagonize IL6-type cytokine sig-
naling were anti-human IL6 (R & D Systems Cat# MAB206, RRID:
AB_2127617), anti-human IL6R𝛼 (R&DSystemsCat#MAB227, RRID:
AB_2127908) and anti-human OSM (R & D Systems Cat# MAB295,
RRID: AB_2298931).
2.2 Cytokine expression analysis
in HCC/PBMC cocultures
The experiment was performed as described61 with minor changes.
The cryopreserved PBMCs were from Zenbio. Huh7 and Hep3B
(7 × 104 per well) were pre-incubated in 48-well plates (in RPMI
medium) with or without 100 ng/ml of IL27 for 24h. They were
then washed 3 times with RPMI and incubated for 3 days with
PBMC (3 × 105 per well) in the presence of Immunocult human
CD3/CD28 T Cell activator (8 𝜇l per well, Stemcell technologies) and
a neutralizing anti-PD-L1 antibody (eBioscience, Cat# 16-5983-82,
RRID:AB_469180; 10 𝜇g/ml). The cell culture supernatants were col-
lected and applied to a Q-Plex human cytokine array IR (Quansys bio-
sciences), according to the manufacturers protocol. The fluorescent
signalswere detected on anOdyssey Infrared Imaging System (Li-COR
Biosciences) and quantitated using theQ-view software (Quansys bio-
sciences) according to the manufacturer’s protocol. Detections of sin-
gle cytokines by ELISA were performed using the IL2 (#88-7025-88)
and IL6 ELISA kits (#88-7066-88) from Invitrogen according to the
manufacturer’s protocol.
2.3 Cell lysis andWestern blot analysis
Cell lysis was performed as described before.62 Proteins were
separated by SDS-PAGE, followed by electro-blotting onto a
PVDF membrane (PVDF-PSQ or PVDF-FL, Millipore). The follow-
ing antibodies were used: STAT3 (BD Biosciences Cat# 610190,
RRID:AB_397589), phospho-STAT1 (pSTAT1) (BD Biosciences Cat#
612233, RRID:AB_399556), STAT1 (BD Biosciences Cat# 610116,
RRID:AB_397522), tubulin (Santa Cruz Biotechnology Cat# sc-
32293, RRID:AB_628412), phospho-STAT3 (pSTAT3) (Cell Signaling
Technology Cat# 9145S, RRID:AB_561305), TAP2 (Cell Signaling
Technology Cat# 12259 RRID:AB_2619687), Vinculin (Abcam Cat#
ab18058, RRID:AB_444215), phospho-STAT5 (pSTAT5) (BD Bio-
sciences Cat# 611965, RRID:AB_399386), phospho-STAT4 (pSTAT4)
(Cell Signaling Technology Cat# 4134S, RRID:AB_11179071), IDO-1
(Cell Signaling Technology Cat# 86630, RRID: AB_2636818). The
4 SOCS3 antibodies tested here were i) Santa Cruz Biotechnology
Cat# sc-7009, RRID:AB_2193311, ii) Santa Cruz Biotechnology
Cat# sc-73045, RRID:AB_1129585 iii) Cell Signaling Technology
Cat# 2932, RRID:AB_2286460 and iv) IBL-America Cat# JP18395,
RRID:AB_1643379. The HRP-conjugated secondary antibodies were
purchased from Cell Signaling. Signals were detected using an ECL
solution containing 2.5 mM luminol, 2.6 mM hydrogen peroxide,
100 mM Tris/HCl pH8.8 and 0.2 mM para-coumaric acid63 and a
CCD camera system (BioRad) or an Odyssey Infrared Imaging System
(Li-COR Biosciences). The fluorescently labelled secondary antibodies
(IRDye 680RD and IRDye 800CW) were from Li-COR Biosciences.
Quantitation of the fluorescent signals was performed on single
channels with the analysis software Image Studio Lite V4.0 provided
by LI-CORBiosciences (Lincoln, NE, USA) as described before.50
2.4 Quantitative PCR
RNA extraction and qPCR was performed as described before.50
Primers were purchased from Eurogentech and the sequences
were as follows: IL27R𝛼-F (GCATCCTATTCTTGTGGGG), IL27R𝛼-R
(CACTTTGTGCCTTAGGTGGT), IL6R𝛽-F (TGAAACTGCTGTGAAT-
GTGG), IL6R𝛽-R (CATCCTTCCCACCTTCATCT), SOCS3-F (ATGA-
GAACTGCCAGGGAATC), SOCS3-R (CCCAGGCTCCACAACCA).
2.5 Reporter gene assays
Cells were reverse transfected on a 96 well plate with 0.1-0.2 𝜇g
of the respective reporter gene construct using Lipofectamine 2000
(Life Technologies) transfection reagent or PromoFectin-Hepatocyte
(for Hep3B, PromoCell). Twenty four hours after transfection, cells
were stimulated for 24 h as described in the figure legends. Lysis
and luciferase assay were carried out as described before.64 Exper-
iments were performed at least in biological triplicate, each with 3
technical replicates. Figures show a representative biological replicate
with mean and standard deviation calculated from 3 technical repli-
cates. The STAT3 specific luciferase reporter, pXP2d2-rat pancreatitis-
associated protein 1 (rPAP1), was described earlier.65
2.6 Flow cytometry
Cells were re-suspended in cold PBS supplemented with 5% FBS
and 0.1% sodium azide (PBS/azide) and incubated with anti-
HLA-ABC-PE (MHC1, Immunotools, Germany, Cat# 21159034,
RRID: AB_2629494), anti-IL6R𝛽-PE (BD Biosciences, USA,
Cat#555757, RRID: AB_396098), anti- IL27R𝛼-PE (R & D Systems,
USA, Cat# FAB14791P, RRID:AB_10718687), and anti-CD274-PE
(PD-L1, eBioscience, USA, Cat# 12-5983-42, RRID:AB_11042286),
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or corresponding IgG control antibodies for 1 h at 4◦C. Cells were
then washed with PBS/azide. Cells analyzed on a FACSCanto II flow
cytometer using FACSDiva software (BD Biosciences). Overlays were
created using the FlowJo software.
2.7 Whole genomemicroarray analysis
The cell lines (PH5CH8, Hep3B, Huh7, NHEM, A375, MelJuso,
NCM460, HCT116 and HT29) were left untreated or were stimulated
with hyper-IL6 (hy-IL6)66 (20 ng/ml), OSM (20 ng/ml), IFN-𝛾 (50 ng/ml),
or IL27 (50 ng/ml) for 24 h. Total RNA was extracted using Quick-
RNA (Zymo Research, USA). For each treatment, two independent
biological replicates were analyzed. RNA integrity was verified with
a Bioanalyzer 2100 (Agilent, USA) and only RNA with a RIN > 8
was used. Gene expression profiling experiments were performed
using the Affymetrix HTA v.2.0 arrays according to the GeneChip WT
PLUS Reagent Kit manual (Target Preparation for GeneChip Whole
Transcript (WT) Expression Arrays P/N 703174 Rev.2 2013 protocol).
A total of 100 ng of RNA was used as starting amount for microarray
experiments. Microarray data were normalized and summarized to
gene level by using the RMA67 algorithm with GC correction in the
Partek Genomics Suite software, v. 6.6. In order to remove uninforma-
tive features, only geneswith a log2 expression level above 5 in at least
one sample were considered for further analysis. Statistical analysis
was performed in R68 and using linear models in an empirical Bayesian
approach implemented in the R/Bioconductor package limma.69 A
global linear model accounting for cell lines and treatments was fit,
and then P-values were estimated for various contrasts. P-values
were adjusted for multiple comparison by Benjamin-Hochberg’s FDR
method70 and genes with FDR< 0.05were selected.
2.8 Principal component analysis
The microarrays of the cell lines responding to the 4 cytokine treat-
ments (PH5CH8, Hep3B, Huh7, NHEM, A375, NCM460 and HT29)
were subjected to principle component analysis (PCA). Computation
and plotting were performed using R (v3.4.0)68 and Rstudio (v1.1).71
The PCAwas computed using the R package FactoMineR (v1.36)72 and
plotted by the R package factoextra (v1.0.4).73 Other plots were gen-
erated using the R package ggplot2 (v2.1)74 and the collection of pack-
ages tidyverse (v1.1).75 All experimentswere scaled to the same unit, as
the IFN-𝛾 stimulation for the NHEM cells possessed a larger variance
compared to the other experiments.
3 RESULTS
3.1 IL27 triggers phosphorylation of STAT1
and STAT3 transcription factors inmany different
cancer cell lines
IL27 has been described to use the ubiquitously expressed common
signal transducing receptor of the IL6-type cytokines, IL6R𝛽 , in combi-
nation with IL27R𝛼. We stimulated a number of cancer and noncancer
cell lines from various tissues (seematerials andmethods) with IL27 to
test their responsiveness (Fig. 1A). Phosphorylationof theSTAT factors
was investigated by Western blot analysis after one hour of stimula-
tion. The cell lines all reacted to IL27 with a robust phosphorylation of
STAT1 (pSTAT1) and a phosphorylation of STAT3 (pSTAT3), the latter
being only slightly over background for some of the cell lines. STAT5
and STAT4 were not phosphorylated by IL27 in any of the cell lines
(Data no shown).
Using flow cytometry we analyzed the surface expression of the
IL27 signaling receptors, IL6R𝛽 , and IL27R𝛼, on a selection of cell lines
(Fig. 1B) and found that both receptors were expressed on the surface
of all investigated cell lines.
3.2 In contrast to IFN-𝜸, IL27 induces a stronger
STAT3 phosphorylation, which is insufficient to
activate STAT3-mediated reporter gene transcription
We compared the STAT1/3 phosphorylation pattern obtained for IL27
signaling to efficient activators of each type of STAT (OSM for STAT3
and IFN-𝛾 for STAT1) by Western blot immuno-detection analyses in
a number of cell lines (Fig. 2A). IL27-mediated STAT1 phosphorylation
was robust, as for IFN-𝛾 , and STAT1 protein expression was induced.
As expected, OSM did not induce STAT1 protein up-regulation. Phos-
phorylation of STAT3 by IL27 was generally weaker than that induced
by the strong STAT3 activator OSM. Thus, IL27 stimulates many cell
types resulting in robust phosphorylation of STAT1 and a less efficient
STAT3 phosphorylation (compared to IFN-𝛾 andOSM, respectively).
To test for transcriptional activity of STAT3 downstream of IL27
we used a STAT3-specific reporter gene assay containing the rPAP1
promotor,65 which is very sensitive and highly specific for STAT3
(Fig. 2B).50 IL27, as IFN-𝛾 (which in contrast to IL27 only leads to
STAT1 phosphorylation), did not activate the STAT3-specific reporter
gene construct,whereas hy-IL6- andOSM-induced transcription of the
reporter gene. Of note, Hep3B cells do not express the oncostatin M
receptor (OSMR) and thus do not activate reporter gene expression
uponOSM.50 Thus, although IL27 led to detectable STAT3 phosphory-
lation, it did not induce STAT3-specific promotor construct transcrip-
tion (similarly to IFN-𝛾 , which does not trigger STAT3 phosphorylation
in our system).
3.3 IL27 and IFN-𝜸 stimulations lead to similar
transcriptome expression profiles
The fact that we did not detect STAT3-dependent reporter gene
activity led us to compare the IL27, IFN-𝛾 , IL6, and OSM responses
in a set of microarrays of cancer and noncancer cell lines of different
tissue origin. We performed a PCA of the dataset to compare the IL27
response to those of the STAT1 (IFN-𝛾) or STAT3 (hy-IL6, OSM) acti-
vating cytokines. The percentile variance of the dataset contributed by
the different dimensions of the PCA was 40% for the first dimension,
whereas the succeeding dimensions account for 13.7 and 9.8% (data
not shown). The first two dimensions of the PCA represent 53.7% of
the total variance of the dataset, and contain most of the information
on the variance related to cytokine stimulation. This value is significant
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F IGURE 1 Cancer cell lines of different origin are sensitive to IL27 stimulation. (A) A panel of cancer and noncancer cell lines of different tissue
origin was stimulated for 1 h with IL27 or was left untreated. Lysates were analyzed by Western blot immuno-detection, using phospho-specific
antibodies against pSTAT1, pSTAT3. Anti-tubulin immuno-detection was performed as loading control. (B) Different cell lines were incubated with
antibodies against IL6R𝛽 or IL27R𝛼 and analyzed by flow-cytometry as described inmaterials andmethods
because it is greater than the reference value of 10.2% (obtained by
the R package FactoInvestigate v1.076), which is the 0.95-quantile of
the variable percentage distribution obtained by stimulating 616 data
tables of equivalent size on the basis of a normal distribution. Analysis
of the first two dimensions of the PCA shows that for most cell lines
the projection of the “combined effect” for the different cytokine treat-
ments (represented by the direction of the arrows) show orthogonal
orientations when comparing the hy-IL6 or OSM effect to the ones
of IL27 or IFN-𝛾 (Fig. 3A and Supporting Information Fig. 1A and1B).
Orthogonal orientation between these “combined effects,” represent-
ing, for example, the hy-IL6- and IL27-responses, indicates that overall
those genes, which are regulated by one of the treatments, are not
regulated by the other. IL27 and IFN-𝛾 showed an almost identical ori-
entation, which is indicative of very similar responses. The same effect
was observed when comparing the hy-IL6 to the OSM responses. In
summary, the IL27 and IFN-𝛾 transcriptomic responses were very
similar throughout all cell lines and cell types (Fig. 3, Supporting Infor-
mation Fig. 1A and B), and they did not regulate genes characteristic
of an IL6-type cytokine response. The NHEM cells did not show such a
clear distinction between the IL6 andOSM responses compared to the
IL27 and IFN-𝛾 responses. Especially the IFN-𝛾 response was shifted
toward an intermediate direction between IL6-type cytokines and the
interferon-like responses. Closer examination of this phenomenon
showed that the different behavior could be attributed to the fact
that the IFN-𝛾 stimulation for this cell line possessed a larger variance
compared to the other cell lines (data not shown). Because the IFN-𝛾
stimulation serves as a control stimulus of a STAT1-activating cytokine,
this interferes with the interpretation of the results for this particular
cell line.
A closer inspection of the differentially regulated genes showed
that IFN-𝛾 and IL27 efficiently upregulate genes involved in anti-
gen presentation, which are important for a potential “anticancer”
cytokine. IFN-𝛾 and IL27 treatment upregulated the expression of
proteasomal subunits, HLA subunits, TAP transporters and other
molecules involved in tumor antigen presentation. In addition,
chemokines associated with a TH1 response and the suppression of
angiogenesis were also upregulated (CXCL9, CXCL11) (Fig. 3B).
Interestingly, the microarray analyses also revealed that IFN-𝛾 and
IL27 regulate a set of genes associated with immune evasion of cancer
(Fig. 3C). In a potential cancer treatment involving IL27, however,
immune-inhibitory proteins such asCD274 (hence forward referred to
as PD-L1), IDO-1, IL18BP, or LAP3 might prevent an efficient immune
clearance and instead induce immune tolerance. These genes were
described to limit inflammation and tissue destruction upon IFN-𝛾
and IL27 stimulation. In chronic cancer inflammation these genes are
associated with a bad prognosis.
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F IGURE 2 IL27 stimulation induces a robust STAT1 phosphorylation. (A) Different cell lines were stimulated for 1 or 24 h with OSM, IL27, or
IFN-𝛾 or were left untreated. Lysates were analyzed by Western blot. Anti-tubulin and -vinculin were used to show equal loading. (B) Different
cell lines were transfected with the STAT3-specific reporter gene plasmid (under the control of the rPAP promotor). 24 h after transfection the
cells were stimulated for 24 h with IL27, OSM, hyperIL6, or IFN-𝛾 or were left untreated before lysates were prepared and luciferase activity
wasmeasured
3.4 IL27 and IFN-𝜸 differentially regulate proteins
involved in antigen presentation and immune escape
in HCC cells and nontransformed liver cells
Validation of some interesting genes at the protein level was per-
formed by flow cytometry (MHC-I, PD-L1) or byWestern blot analysis
(STAT1, TAP2, IDO-1) in different cell types (Fig. 4 and Supporting
Information Fig. 2). Because HCC is our main focus,50 we also per-
formed quantitativeWestern blot analysis for threeHCC cell lines and
the PH5CH8 cells for several proteins (Fig. 4D). In general, proteins
associated with increased immune clearance of cancer such as Tap2
and MHC-I were upregulated upon IL27, IFN-𝛾 and IFN-𝛼 treatment,
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F IGURE 3 IL27 recapitulates an IFN-𝜸-like transcriptomic response. (A) Representation of dimensions 1 and 2 of a PCA of microarray data of
cells stimulated as indicated. Arrows (one for each treatment in each cell line) represent the projection of the total contribution of all differentially
regulated genes of this treatment. For visualization reasons this figure shows only the cell lines of hepatic origin (for colon and skin cells see Sup-
porting Information Figure 1A and 1B). The colored ellipses show the 0.95% quantile distribution of validated STAT1- (yellow) or STAT3-regulated
genes (rose). Individual genes are represented as gray spots. For detailed lists see Supporting Information Figures 1C and D. (B) Heatmap repre-
senting the regulation of genes involved in antigen presentation or induction of TH1 responses. (C) Heatmap representing the regulation of genes
involved in immune escape. Heatmaps were drawn using the R package ggplot274
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F IGURE 4 Validation of IL27 gene regulation on protein level. (A) 2C4, A375, and A431 cells were stimulated for 24 hwith IL27, OSM, or IFN-𝛾
or were left untreated.Western blots of the lysates were immuno-detected using antibodies against TAP2, STAT1, and vinculin (the latter to show
equal loading). (B) Expression ofMHC1was studied by flow cytometry in cells stimulated withOSM, IL27, or IFN-𝛾 for 24 h. A representative from
2 biological replicates is shown. (C) Expression of PD-L1 was studied by flow cytometry in a panel of cancer cell lines. Cells were left untreated
or stimulated with OSM, IL27, or IFN-𝛾 for 24 h. A representative of 3 biological replicates is shown. (D) HepG2, Hep3B, Huh7, and PH5CH8 cell
lines were stimulated for different time points with IL27, OSM, or IFN-𝛾 or were left untreated. Western blots of the lysates were then immuno-
detected using antibodies against IDO-1, TAP2, and STAT1 and quantitated as described in materials and methods and represented as relative
signal intensity compared to the strongest signal on the blots (mean and standard deviation of 3 biological replicates are shown). Tubulin served as
control detection (see also Supporting Information Figure 2C)
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but not after OSM or hy-IL6 treatment in different cell types (Fig. 4A
and B and Supporting Information Fig. 2A and C) (for HCC cells see
also50). Thus, IL27-treated cells are likely to present more antigen on
the cell surface than untreated cells. FACS analysis showed that IL27,
IFN-𝛾 , and IFN-𝛼 led to an efficient PD-L1 protein up-regulation in
different cancer cell lines, and again,OSMorhy-IL6did not (Fig. 4Cand
Supporting Information Fig. 2B). Interestingly, quantitative Western
blot analysis revealed that IDO-1 was inefficiently induced by IL27
in contrast to STAT1 or TAP2, whereas IFN-𝛾 induced IDO-1 more
efficiently (Fig. 4D and Supporting Information Fig. 2C). In addition,
IDO-1 protein induction was especially strong in the IFN-𝛾-stimulated
nontransformed cell line PH5CH8.
In summary, IL27, like IFN-𝛾 , induces protein expression associated
with increasedantigenpresentation (TAP2,MHC-I) and tumor immune
escape (PD-L1).
3.5 In cocultures of HCC and PBMC, HCC
cell-expressed PD-L1 can suppress IL2 production
in anti-CD3/-CD28 activated T lymphocytes
To analyze if IL27-mediated PD-L1 expression in HCC cells can have
an immune-suppressive effect, we performed coculture experiments
in which we pre-stimulated HCC cells with IL27 for 24 hours, washed
IL27 away and incubated the PD-L1-expressing HCC cells with anti-
CD3/CD28-activatedPBMCs for 3 days (Fig. 5A). Pre-treatment of the
HCC cells with IL27 resulted in lower IL2 production in the coculture,
which shows that PD-L1 expressed at the surface of the HCC cells
can influence T-cell functions (Fig. 5B). Addition of a blocking PD-L1
antibody (concomitantly with the PBMCs), raised the IL2 secretion at
least to the level observed before (or higher) (Fig. 5B and Supporting
Information Fig. 3A). The levels of other pro-inflammatory cytokines
(e.g., IL1𝛽 , TNF-𝛼, and MCP1) were either restored or upregulated by
anti-PD-L1 administration (Fig. 5C). However, IL6 levels, a cytokine
described tomediate “pro-tumor” effects, were also decreased by IL27
treatment and efficiently increased upon anti-PD-L1 administration
(Fig. 5D and Supporting Information Fig. 3B).
3.6 The inhibition of IL27 responses
by IL6-type-cytokines is prevented by administration
of blocking antibodies against these cytokines
or their receptors
IL27 signaling is susceptible to inhibition by SOCS3, which is induced,
for example, upon phosphorylation of STAT3 by IL6-type cytokines.50
IL6-type cytokine and non-IL6-type cytokine-mediated STAT3 phos-
phorylation is often observed in a cancer-associated inflammatory
context and is thought to have “pro-tumor” effects77 (see also Support-
ing Information Fig. 5). In addition, as shown in Figure 5, IL6 levels are
also upregulated upon anti-PD-L1 administration.
To mimic cancer-associated constitutive activation of STAT3, we
pre-stimulated the cells with OSM, hy-IL6 or left them untreated for
4 h before a 24 h stimulation with IL27. To monitor IL27-induced
responses, we measured PD-L1 surface expression by flow cytometry
anddetected STAT1, TAP2, and IDO-1byWestern blot analysis inHCC
cell lines. OSM or hy-IL6 pre-stimulation (Fig. 6A, solid line) reduced
the IL27-dependent PD-L1 up-regulation (Fig. 6A, red peak) almost
to the level of the non-IL27-stimulated sample (Fig. 6A, gray peak).
Treatmentwith anti-cytokineor anti-cytokine receptor antibodies effi-
ciently restored IL27-induced PD-L1 expression (Fig. 6A, dotted line).
The identical observations were made for STAT1, TAP2, and IDO-1 as
investigated by Western blot analysis (Fig. 6B). Thus, an anti-IL6-type
cytokine approach might have beneficial effects in IL27 antitumor
treatment, if constitutive STAT3 phosphorylation is observed. We
have described before that IL27 can be inhibited by SOCS3 (which
is a STAT3 target gene). We show that phosphorylation of STAT3
(Fig. 6B, lower panels) and up-regulation of SOCS3 mRNA (Fig. 6C)
and protein (see Supporting Information Fig. 4) are suppressed by
anti-IL6 treatment.
4 DISCUSSION
We show and discuss in the following that (i) IL27 induces STAT
factor phosphorylation in cancerous cells lines of different tissue
origin. (ii) IL27 leads to STAT1 phosphorylation and recapitulates an
IFN-𝛾-like response in the microarray analyses, with up-regulation of
many genes involved in antiviral defense, antigen presentation and an
up-regulation of some genes involved in immune escape. (iii) However,
the STAT3 response to IL27 remains elusive and a sensitive STAT3
reporter gene construct did not respond to the IL27 stimulus. (iv) Like
IFN-𝛾 , IL27 leads to an up-regulation of TAP2 and MHC-I protein,
which are associated with an increased tumor immune clearance.
However, both cytokines also upregulate proteins such as PD-L1
(CD274) and IDO-1, which are associated with an immune escape
of cancer. (v) PD-L1 up-regulation upon IL27 treatment reduced IL2
secretion in coculture experiments ofHCCcells andPBMCs, but block-
ing antibodies targeting PD-L1 overcompensated the effect and led to
significantly enhanced secretion of IL2. (vi) Finally, the attenuation of
IL27 responses by pre-stimulation with IL6-type cytokines can be pre-
vented by use of anti-cytokine antibodies. Thus, this might represent
a possible co-treatment option with IL27 in IL6-type cytokine-
expressing tumors or in case of tumor-induced systemic inflammation.
We investigated a number of cell lines from various tissue ori-
gins concerning their responsiveness to IL27. IL27 induced a robust
phosphorylation of STAT1 and a phosphorylation of STAT3, the lat-
ter being only slightly over background for some of the different cell
lines (Fig. 1A). The investigated cells also expressed the IL6R𝛽 and
IL27R𝛼, the canonical receptor subunits for IL27 signaling (Fig. 1B).50
Since IL27 is a noncovalent dimer of the EBI3 and p28 subunits,
a dissociation of IL27 in the presence of other competing cytokine
subunits (p35, CLF1) might occur. p28 alone or in complex with
CLF1 (cytokine-like factor 1) has been described to signal through
IL6R𝛼/ IL6R𝛽 (although only at high cytokine concentrations) to
activate STAT3,78,79 which (i) is described to be pro-tumorigenic80
and (ii) can inhibit IL27 signaling (by SOCS3 induction).50 p28 (also
called IL30) expression correlates with advanced grade of prostate
cancer and promotes breast cancer growth.81,82 In addition, local
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F IGURE 5 Cytokine expression from cocultures of PBMCs with IL27-pre-stimulated HCC cells in presence or absence of a blocking anti-PD-
L1 antibody. (A) Scheme of the experimental layout. (B to D) Cytokine levels were analyzed by cytokine arrays. IL2 (B), MCP1, IL1𝛽 , TNF-𝛼 (C) and
IL6 (D) levels are expressed as themean± standard deviation of 3 biological replicates. One-way ANOVAwith Bonferroni posttest was performed
using Graphpad InSTAT version 3.10 (www.graphpad.com). For statistical analysis error probabilities <0.05 were considered to be significant,
***: P< 0.001, **: P< 0.01, *: P< 0.05
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F IGURE 6 Blocking antibodies against IL6-
type cytokine or receptors prevent down-
regulation of IL27 signaling. (A) Expression of
PD-L1 on the HCC cell lines HepG2, Huh7, and
Hep3B was studied by flow-cytometry. Cells
were left untreated (gray fill) or were stimulated
with IL27 alone (red fill) or treated for 4 h with
hy-IL6 or OSM prior to the IL27 treatment for
24 h (solid line). The dotted line indicates the sit-
uation in which blocking antibodies against IL6,
IL6R, or OSM were added together with the IL6
orOSMpre-treatment. (B) HepG2, Hep3B, Huh7,
and PH5CH8 cells were stimulated as described
in (A) but using only hy-IL6 and anti-IL6. Western
blots of the lysates were immuno-detected for
the STAT1 target genes IDO-1, TAP2, STAT1.
Vinculin and tubulin detections were used as
loading controls. Phosphorylation of STAT3 was
investigated on a separate blot using STAT3, vin-
culin and tubulin as controls. (C) HepG2, Hep3B,
Huh7, and PH5CH8 cells were stimulated as
described in (B). The cells were lysed after 6
h of treatment. SOCS3 mRNA expression was
investigated by qPCR. Results show the mean
of 3 biological replicates as a percentage of the
highest SOCS3 inductionwith standard deviation
expression of p35 (a subunit of IL12), could lead to competitive dis-
placement of p28 fromEBI3, to form IL35 (composed of EBI3 and p35),
a cytokine that exerts its immunosuppressive functions by promot-
ing iTreg differentiation and activity.83,84 Thus, IL27 administration as
a potential anticancer treatment should rather be performed with a
covalently linked dimer of p28 and EBI3 to avoid the aforementioned
pro-tumorigenic effects.
With respect to STAT factor activation, almost all tested cells
reacted to IL27 with a robust phosphorylation of STAT1 (comparable
to the IFN-𝛾 response) and a phosphorylation of STAT3, the latter
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being weaker compared to the OSM-induced STAT3 phosphory-
lation (Fig. 2A). Because studies in immune cells have discussed a
role of STAT3 in transcriptional responses through IL27,85–87 we
tested for the presence of transcriptionally active STAT3 by using the
STAT3-specific and very sensitive rPAP reporter gene construct
(Fig. 2B). Only OSM, but not IL27 or IFN-𝛾 , induced STAT3-dependent
reporter gene transcription in the tested cells of different tissue types.
The possible reasons for such an inefficient STAT3 response have been
discussed in detail before.50
Whole genome microarray analyses of 7 cell lines (3 different tis-
sue types) stimulatedwith IL27, IFN-𝛾 , hy-IL6, orOSMshowed that the
IL27 response closely recapitulates an IFN-𝛾 response (Fig. 3 and Sup-
porting Information Fig. 1A and B). IL27, like IFN-𝛾 , regulates mRNAs
involved in immune regulation and antigen presentation but is also
related to other canonical functions of IFN-𝛾 , for example, the antivi-
ral defense (data not shown). In the antigen presentation pathway,
genes encodingMHC-I subunits (HLA-A, -B, -E, -G, B2M), the immuno-
proteasome (PSMB-8 to -10), the S11 proteasome (PSME-1 and -2),
and TAP transporters (TAP1 and 2) were upregulated (Fig. 3B). The
up-regulation of the antigen presentation pathway is associated with
increased immunogenicity of tumors. In addition, CXCL9 and 11 were
upregulated, which promote anti-angiogenesis and recruit immune
cells associated with TH1 responses. Interestingly, a subset of genes
involved in immune escape of cancer (LAP3, IL18BP, IDO-1, and PD-L1
(CD274)) were also upregulated by IL27 and IFN-𝛾88 (Fig. 3C). These
genes can promote immune evasion of cancer if overexpressed, as part
of a dysregulated interferon response.89 Very recently, a number of
the proteins mentioned earlier was found to be upregulated by IL27
in ovarian cancer, neuroblastoma, and lung adenocarcinoma cells.88,90
IL27 upregulates PD-L1 in leukocytes37,38,91,92 and other cell types
including cancer cells.61,90,93,94
In the subsequent validations we showed that IL27, like IFN-𝛾 ,
also upregulates the protein levels of a number of genes involved in
increased cancer immune clearance (STAT1, TAP2, MHC-I) and pro-
teins involved in immune escape of cancer (PD-L1, IDO-1) (Fig. 4 and
Supporting Information Fig. 2). Interestingly, PD-L1 is upregulated fol-
lowing IL27 and IFN-𝛾 stimulation, but not upon OSM in all tested
cell lines.
Because HCC was our main focus here and represents a tumor
with still limited treatment options, we tested the induction of the
aforementioned genes in more detail in these cells and in the non-
transformed PH5CH8 liver cell line (Fig. 4D). The liver is character-
ized by an intrinsic immune suppressive microenvironment, which has
been described to impede the effectiveness of anticancer vaccines.95
Moreover, HCC is known to lack the antigen processing proteins nec-
essary to present tumor antigens,which allows escape fromCD8+ lym-
phocyte killing.31 However, reactivation of different types of immune
cells, such as cytokine-induced killer cells, NK cells or DCs pulsed with
tumor lysate have been shown to be effective in clinical and preclin-
ical studies (reviewed in95). Therefore, we reason that HCC antigen
presentation and a subsequent immune reactivation might be achiev-
able by using IL27. Whereas MHC-I, STAT1, and TAP2 proteins were
expressed in IL27- and IFN-𝛾-treated cells, IDO-1 was less efficiently
induced in IL27-treated cells. Interestingly, the induction of IDO-1
and, to a much lesser extent, TAP2 vary when comparing the IFN-𝛾
and IL27 responses. This effect was not observed at the level of
STAT1 protein induction, possibly, due to a different sensitivity of the
different genes toward phosphorylated STAT1. Because IL27 gener-
ally shows a slightly weaker induction of STAT1 phosphorylation in
HCC cells50 than IFN-𝛾 , it might generally induce less IDO-1. On the
other hand, PD-L1 expressionwas equally efficientlymediated by IL27
and IFN-𝛾 .
Thus, IL27 and IFN-𝛾 can have immune-promoting functions but
could also lead to tumor immune escape, a characteristic that might
interfere with tumor clearance upon a potential IL27 therapy. Because
the PD-L1 gene is efficiently induced by IL27, IL27 immune therapy
might profit from anti-PD-L1 antibody co-treatment. Targeting PD-
L1/PD-1 has shown impressive antitumor effects in solid tumors,96–99
including HCC.100 Clinical trials using immune checkpoint inhibitors,
for example, anti-CTLA4 and anti-PD-1, demonstrated that the
treatment was well tolerated.100 In coculture experiments of HCC
cell lines with PBMCs we could show that an IL27-dependent PD-L1
expression on HCC cells can decrease IL2 production by the PBMCs.
Interestingly, a blocking anti-PD-L1 antibody could again increase
IL2 secretion. (Fig. 5B).61 The levels of other pro-inflammatory
cytokines were also restored or upregulated by anti-PD-L1
administration (Fig. 5C).
IL6, a “pro-tumor” cytokine, was also secreted into coculture super-
natants upon anti-PD-L1 administration (Fig. 5D). IL6 and OSM were
shown to be present in inflammatory tumors. Inflammation has been
established to be involved in cancer development,101 and constitutive
activation of STAT3 found in many cancers is mediated by different
mechanisms.57,58,80,102–104 In addition, IL6-type cytokines have been
shown to be essential players in the development of at least colon and
liver cancers.55,77,105,106 Wehave shownbefore that IL6-type cytokine
pre-stimulation, which induces SOCS3 expression, can suppress a sub-
sequent IL27-response in a SOCS3-dependent manner.50,107 Due to
this cross-inhibition of “pro-tumor” IL6-type cytokines, IL27 responses
and thus its antitumor efficacy might be considerably reduced in
“inflammatory” tumors.Wenowshow that anti-IL6-type cytokine anti-
bodies can reconstitute efficient IL27 responses (Fig. 5).
In addition, IL6 canhaveother immunosuppressiveeffects in cancer.
Tumor-induced systemic IL6 can induce systemic metabolic changes.
It induces lipolysis of white adipose tissue, which can cause hyperlipi-
demia and results in insulin resistance of skeletal muscle (reviewed
in108). In the liver, IL6 inhibits PPAR𝛼, which reduces ketone genera-
tion under lowenergy/insulin resistance. The resulting hypoketonemia
stimulates the adrenal gland to induce glucocorticoids, which suppress
intratumoral immunity and even prevent anticancer immunotherapy
with anti-PD-L1 antibodies.109 In addition, IL6 can act locally in the
tumor on immune cells to suppress anticancer immunity (reviewed
in33). IL6 favors the development of M2 macrophages, MSDCs and
TH17 cells, which is associated with secretion of immunosuppres-
sive factors such as IL10 and IL4 (which again inhibit TH1 cells,
CD8 positive CTLs and NK cells). Cancer-associated fibroblasts and
regulatory B cells have also been described to secrete IL6. Thus,
blocking IL6 in patients with a prominent tumor-induced IL6-type
cytokine-dependent inflammation might have more anticancer effects
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F IGURE 7 Major IL27-mediated signaling pathways in cancer cells and possible treatment options to improve immune clearance of cancer
cells. Pathways and treatments that promote antitumor actions are indicated by blue arrows. Pathways that promote tumor immune escape are
indicated using red arrows. Black boxes indicate those blocking antibodies that have been used in this study. Already FDA-approved blocking anti-
bodies inhibiting the same targets mentioned above are shown in dark green boxes. An IDO-1 inhibitor that entered clinical trials but is not yet
FDA-approved is indicated in a grey box. In tumorswith high IL6-type cytokine levels, anti-cytokine-receptor- or anti-cytokine-antibodies could be
used in addition to IL27, to relieve the SOCS3-mediated cross-inhibition of IL6-type cytokines on IL27 signaling. PD-L1 is expressed in all investi-
gated cancer cell types in response to IL27 and thus anti-PD-L1 antibodies could be envisaged as standard co-treatment with IL27 (or Interferon-)
therapies to prevent immune cell deactivation (e.g., a CD8+T-cell as shown in the scheme) by cancer cell-expressed PD-L1. IDO-1 is not induced by
IL27 in all cells and thus IDO-1 inhibitor treatment could only be applicable to a subset of tumors
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than just preventing the inhibition of a potential IL27 treatment
(see also Supporting Information Fig. 5).
In summary, we hypothesize that HCC (characterized by an intrin-
sic immune suppressive microenvironment) could benefit from IL27
treatment, which upregulates proteins involved in antigen presenta-
tion (Fig. 7). In addition, a co-treatment with anti-PD-L1 or anti-PD-1
antibodies might prevent immune suppressive effects also mediated
by prolonged IL27 or interferon stimulation. A number of studies even
suggested that blockade of the PD-1/PD-L1 pathway is a prerequisite
for the necessary stimulatory functions of interferons in the antitu-
mor response.110–114 Due to the suppression of IL27 signaling, medi-
ated by IL6-type cytokine-induced SOCS3 protein, patients with high
circulating IL6 levels (e.g., by cancer inflammation-associated cachexia
or IL6 producing tumors) will very likely only be responsive to IL27
treatment if an anti-IL6-type cytokine or anti-IL6-type cytokine recep-
tor antibody is used in combination. Last but not least, IL27 responses
are not restricted to the cancer cell itself. IL27-induced TH1 responses
in immune cells are known to be enhanced by blocking PD-L1 and
IDO-1 or other immune-suppressive stimuli. Concomitant blocking of
CTLA4 and PD-L1 has shown significant clinical responses and has
been described to improve antitumor immune responses by mecha-
nisms relying on IFN-𝛾 and IL7 signaling.113 Cytokine induced cancer-
cell (IL27) and immune-cell (IL27, IL7, IL15, IL2, IL12) stimulation com-
bined with blockade of crucial immune checkpoints (𝛼PD-L1, 𝛼CTLA4)
might be what is needed to elicit more effective anticancer responses
in an immuno-suppressive microenvironment.
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